Defence Therapeutics Q2 2024 Investor Presentation

Defence Therapeutics is a Montreal-based publicly traded biotech company with a patented Accum® platform technology that enhances biotherapeutics potency by 10-100X. The company has FDA clearance for Phase 1 testing of AccuTOX for melanoma and significant licensing opportunities in cancer therapeutics and vaccine development.